While evidence for PSMA-targeted therapy in RCC remains limited, vascular PSMA expression shows promise as a predictive biomarker and warrants further investigation in metastatic settings and in combination with existing RCC therapies. This evidence concerns the gene FOLH1 and renal cell carcinoma.